INMB Stock Set for Growth with Positive Analyst Coverage

Lucid Capital has begun its coverage of INmune Bio (INMB, Financial) by assigning it a Buy rating along with a target price of $25. According to the analyst, INmune Bio stands out as one of a handful of companies advancing through mid- to late-stage development in the fight against Alzheimer’s disease. The firm anticipates releasing data from a critical mid-stage Alzheimer’s trial in June, which could solidify the blockbuster potential of the company’s promising Alzheimer’s treatment, XPro.

Wall Street Analysts Forecast

Based on the one-year price targets offered by 5 analysts, the average target price for INmune Bio Inc (INMB, Financial) is $23.40 with a high estimate of $30.00 and a low estimate of $20.00. The average target implies an upside of 221.87% from the current price of $7.27. More detailed estimate data can be found on the INmune Bio Inc (INMB) Forecast page.

Based on the consensus recommendation from 5 brokerage firms, INmune Bio Inc’s (INMB, Financial) average brokerage recommendation is currently 1.8, indicating “Outperform” status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for INmune Bio Inc (INMB, Financial) in one year is $1.17, suggesting a downside of 83.91% from the current price of $7.27. GF Value is GuruFocus’ estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business’ performance. More detailed data can be found on the INmune Bio Inc (INMB) Summary page.

INMB Key Business Developments

Release Date: March 27, 2025

• Net Loss: Approximately $42.1 million for the year ended December 31, 2024, compared to approximately $30 million for 2023.
• Research and Development Expenses: Approximately $33.2 million for the year ended December 31, 2024, compared with approximately $20.3 million for 2023.
• General and Administrative Expenses: Approximately $9.5 million for the year ended December 31, 2024, compared with approximately $9.6 million for 2023.
• Cash and Cash Equivalents: Approximately $20.9 million as of December 31, 2024.
• Additional Capital Raised: $5.4 million through the use of the ATM since year-end.
• Shares Outstanding: Approximately 22.9 million shares of common stock as of March 27, 2025.
• Capital Raised from Common Stock and Warrants: $29.9 million during 2024.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• INmune Bio Inc (INMB, Financial) is less than 100 days away from announcing topline data for their phase 2 trial targeting neuroinflammation in early Alzheimer’s disease, which could potentially transform treatment paradigms.
• The ADO2 trial is unique in its use of biomarkers other than amyloid or tau for patient selection, focusing on neuroinflammation as a primary driver of Alzheimer’s disease.
• INmune Bio Inc (INMB) has completed the pivot to solid tumors with their NK cell targeting platform, showing progress in treating castrate-resistant metastatic prostate cancer.
• The company has raised $29.9 million from the sale of common stock and warrants, with potential to raise an additional $30 million through warrant exercises.
• INmune Bio Inc (INMB) has a promising pipeline with the addition of Chordstrom, a systemic therapy for a rare genetic disease, which has already been awarded orphan drug status and rare pediatric disease designation.

Negative Points

• The company reported a net loss of approximately $42.1 million for the year ended December 31, 2024, compared to $30 million in 2023, indicating increased financial strain.
• Research and development expenses increased significantly to approximately $33.2 million in 2024 from $20.3 million in 2023, reflecting higher costs associated with their clinical programs.
• The company’s cash and cash equivalents stood at approximately $20.9 million at the end of 2024, which may only be sufficient to fund operations through Q3 2025 without additional financing.
• The success of the ADO2 trial is critical, as it is the catalyst for future developments, and any negative results could significantly impact the company’s prospects.
• There is uncertainty regarding the FDA’s acceptance of the novel endpoints used in the ADO2 trial, which could affect the trial’s regulatory approval process.